Tag: NYR
Nyrada announces progress in brain injury study
Nyrada (ASX: NYR) has achieved a milestone in one of its drug development programs for the treatment of brain injury, revealing its lead candidate compounds can cross the blood-brain barrier in the in...
Nyrada advances brain injury and cholesterol lowering studies, remains unaffected by COVID-19
Nyrada (ASX: NYR) revealed this morning it was continuing to make “strong progress” in its two lead drug programs to treat brain injury and lower cholesterol.
The brain injury program is using a ne...
Nyrada CEO James Bonnar discusses the company’s commercialisation plans – Podcast
Junior biotech company Nyrada (ASX: NYR) was the first IPO off the mark for 2020, with the company’s stock floating on the ASX in mid-January after raising the intended maximum of A$8.5 million....
Nyrada cholesterol-lowering drug studies validated in peer reviewed medical journal
Drug discoverer and early stage developer Nyrada (ASX: NYR) has had a significant advance made in the pre-clinical studies of its cholesterol-lowering drug program published in a medical journal.
T...
Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8.5m
Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc (ASX: NYR) experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8...
